Medical News: FDA Updates PML Risk Info for Natalizumab - in Neurology, Multiple Sclerosis from MedPage Today
Links shared publicly online about this topic.
- 346total visits
Medical News: FDA Updates PML Risk Info for Natalizumab - in Neurology, Multiple Sclerosis from MedPage Today
As expected, the FDA has approved new label language for the multiple sclerosis drug natalizumab (Tysabri) with additional detail on the risks of progressive multifocal leukoencephalopathy (PML).
View full resource at medpagetoday.com
Tags: Neurology, Multiple Sclerosis, Multiple Sclerosis Medication, Healthy Living, FDA, Tysabri, News, Medical
Most Recently Shared on April 22, 2011 at 10:06 pm By:
@medpagetoday FDA Updates PML Risk Info for Natalizumab http://bit.ly/i6ZA0J #medical #Health
Also Shared By:
Advertisement
Medical News
@MedicalNews
FDA Updates PML Risk Info for Natalizumab http://bit.ly/i6ZA0J
1 year ago...